This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

VITAL-BE Value of inhaled treatment with Aztreonam in bronchiectasis

  • Research type

    Research Study

  • Full title

    A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis.

  • IRAS ID

    252929

  • Contact name

    James Chalmers

  • Contact email

    j.chalmers@dundee.ac.uk

  • Sponsor organisation

    University of Dundee

  • Eudract number

    2018-001590-24

  • Clinicaltrials.gov Identifier

    NCT03696290

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    Bronchiectasis not due to cystic fibrosis is a chronic inflammatory disease characterised by cough, sputum production and frequent respiratory tract infections. There are currently no licensed therapies for bronchiectasis approved by regulators in the United States or Europe. The disease has a high morbidity, particularly in the presence of chronic Pseuodomonas aeruginosa and other chronic Gram-negative infections. The presence of P. aeruginosa infection is associated with a higher frequency of acute exacerbations, worse quality of life and a three fold increase in mortality.There is a strong rationale for the effectiveness of inhaled antibiotic treatment in bronchiectasis. This trial will examine the safety, efficacy and tolerability of Aztreonam lysine an inhaled antibiotic licensed for use in cystic fibrosis. 100 participants with bronchiectasis and positive sputum culture for a gram negative infection will be randomised to one of four groups: 75mg Aztreonam three times per day, 75mg Aztreonam twice per day or matching placebo two or three times per day. Treatment will continue for 12 months on a month on month off regimen as per usual clinical practice for the use of Aztreonam. The main objectives of the trial are 1) to determine if treatment with Aztreonam lysine for inhalation will be safe and well tolerated as compared to placebo and 2) To determine if Aztreonam lysine for inhalation will result in a significant reduction in the frequency of exacerbations, time to first pulmonary exacerbation and additional clinical benefits in participants with bronchiectasis and a history of frequent exacerbations.

  • REC name

    East of Scotland Research Ethics Service REC 2

  • REC reference

    18/ES/0147

  • Date of REC Opinion

    7 Jan 2019

  • REC opinion

    Further Information Favourable Opinion